The community-acquired bacterial pneumonia market is poised for continued growth, driven by the substantial global disease burden, increasing hospitalization rates, an aging population, rising prevalence of comorbidities, and the growing challenge of antimicrobial resistance. Additionally, the launch of emerging therapies such as CAL02 (Eagle Pharmaceutical/Combioxin), AON-D21 (APTARION Biotech), Trimodulin (BT588; Biotest AG), and others will further propel market growth..

社区获得性细菌性肺炎市场有望持续增长，其驱动因素包括沉重的全球疾病负担、住院率上升、人口老龄化、合并症患病率增加以及抗菌药物耐药性带来的日益严峻的挑战。此外，CAL02（Eagle Pharmaceutical/Combioxin）、AON-D21（APTARION Biotech）、Trimodulin（BT588；Biotest AG）等新兴疗法的上市也将进一步推动市场增长。

LAS VEGAS

拉斯维加斯

,

，

Sept. 7, 2026

2026年9月7日

/PRNewswire/ -- Recently published Community-Acquired Bacterial Pneumonia Market Insights report includes a comprehensive understanding of current treatment practices, community-acquired bacterial pneumonia emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. .

/美通社/ -- 最近发布的《社区获得性细菌性肺炎市场洞察》报告全面解析了当前的治疗实践、社区获得性细菌性肺炎新兴药物、各疗法的市场份额，以及2022年至2036年的当前市场规模和预测市场规模，并按主要市场（美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本）进行了细分。

Community-Acquired Bacterial Pneumonia Market Summary

社区获得性细菌性肺炎市场概览

The total community-acquired bacterial pneumonia treatment market size is expected to grow positively by 2036 in the leading markets.

到2036年，主要市场的社区获得性细菌性肺炎治疗市场总规模预计将实现正增长。

The United States accounted for the largest community-acquired bacterial pneumonia treatment market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

2025年，在七大主要市场（7MM）中，美国占据了最大的社区获得性细菌性肺炎治疗市场规模，其他主要市场包括欧盟四国（德国、法国、意大利和西班牙）、英国和日本。

Around

周围

80%

80%

of the nearly

在将近

4 million

400万

cases of community-acquired pneumonia (CAP) in the US are classified as CABP. This high prevalence of CABP within the broader category of CAP underscores the significant burden of bacterial pathogens in pneumonia cases.

美国的社区获得性肺炎（CAP）病例被归类为社区获得性细菌性肺炎（CABP）。在更广泛的CAP类别中，CABP的高患病率突显了细菌病原体在肺炎病例中的重大负担。

Leading community-acquired bacterial pneumonia companies, such as

社区获得性细菌性肺炎领域的领先企业，例如

Eagle Pharmaceutical, Combioxin, APTARION Biotech, Biotest AG,

鹰牌制药公司，Combioxin公司，APTARION生物技术公司，Biotest股份公司，

and others, are developing new community-acquired bacterial pneumonia treatment drugs that can be available in the community-acquired bacterial pneumonia market in the coming years.

以及其他公司正在开发新的社区获得性细菌性肺炎治疗药物，这些药物有望在未来几年内上市。

The promising community-acquired bacterial pneumonia therapies in clinical trials include

临床试验中前景广阔的社区获得性细菌肺炎疗法包括

CAL02, AON-D21, Trimodulin (BT588),

CAL02，AON-D21，Trimodulin（BT588），

and others.

以及其他。

Discover CABP clinical trial 2026 update press release @

发现2026年社区获得性细菌性肺炎（CABP）临床试验更新的新闻稿 @

https://www.delveinsight.com/report-store/community-acquired-bacterial-pneumonia-cabp-market

https://www.delveinsight.com/report-store/community-acquired-bacterial-pneumonia-cabp-market

Key Factors Driving the Growth of the Community-Acquired Bacterial Pneumonia Market

推动社区获得性细菌性肺炎市场增长的关键因素

Rising Burden of Community-Acquired Bacterial Pneumonia:

社区获得性细菌性肺炎的负担日益加重：

The persistent incidence of community-acquired bacterial pneumonia (CABP), particularly among older adults, children, and individuals with underlying conditions, is driving demand for effective treatment options. The associated morbidity, hospitalization rates, and mortality further support market growth..

社区获得性细菌性肺炎（CABP）的持续发病率，尤其是在老年人、儿童和患有基础疾病的人群中，正在推动对有效治疗方案的需求。相关的发病率、住院率和死亡率进一步促进了市场增长。

Increasing Antimicrobial Resistance:

日益严重的抗菌药物耐药性：

The growing prevalence of antibiotic-resistant bacterial pathogens is creating a need for novel antibiotics and therapies with improved efficacy against resistant strains. This is encouraging pharmaceutical companies to invest in the development of next-generation antibacterial treatments.

抗生素耐药性细菌病原体的日益普遍，使得人们迫切需要开发对耐药菌株具有更好疗效的新型抗生素和疗法。这正促使制药公司加大对下一代抗菌治疗药物研发的投入。

Advancements in Antibiotic Development:

抗生素研发的进展：

Ongoing research into novel antibacterial mechanisms, improved formulations, and targeted therapies is expanding the treatment landscape for CABP. The emergence of differentiated therapies may provide additional options for patients who have limited responses to conventional antibiotics.

针对新型抗菌机制、改良制剂和靶向疗法的持续研究正在拓展社区获得性细菌性肺炎（CABP）的治疗格局。差异化疗法的涌现可能为对传统抗生素反应有限的患者提供额外的治疗选择。

Launch of CABP Drugs:

社区获得性细菌性肺炎（CABP）药物上市：

The dynamics of the CABP market are expected to change in the coming years due to the launch of emerging therapies such as

由于新兴疗法的推出，预计未来几年CABP市场的动态将发生变化，例如

CAL02

CAL02

(Eagle Pharmaceutical/Combioxin),

（伊格尔制药/Combioxin）

AON-D21

AON-D21

(APTARION Biotech),

（APTARION Biotech），

Trimodulin

曲莫杜林

(BT588; Biotest AG), and others.

(BT588；Biotest AG) 等。

Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that emerging candidates such as CAL02 and AON-D21 are being developed to complement conventional antibiotic treatment by targeting bacterial toxins, virulence factors, and host inflammatory responses. These novel approaches aim to improve clinical outcomes in severe CABP and address challenges associated with antimicrobial resistance and treatment failure..

DelveInsight 预测与分析项目经理 Aparna Thakur 表示，CAL02 和 AON-D21 等新兴候选药物正在开发中，旨在通过靶向细菌毒素、毒力因子和宿主炎症反应，作为传统抗生素治疗的补充。这些新颖疗法旨在改善严重社区获得性细菌性肺炎（CABP）患者的临床结局，并应对与抗菌素耐药性和治疗失败相关的挑战。

Community-Acquired Bacterial Pneumonia Market Analysis

社区获得性细菌性肺炎市场分析

Community-acquired pneumonia continues to represent a substantial global health burden, contributing significantly to both morbidity and mortality. Identifying the optimal antibiotic therapy for CAP, however, remains challenging because of several clinical and epidemiological considerations.

社区获得性肺炎（CAP）仍然构成重大的全球健康负担，显著导致发病率和死亡率。然而，由于多种临床和流行病学因素，确定CAP的最佳抗生素治疗方案仍具挑战性。

The treatment landscape is also evolving as the efficacy and safety profiles of established antibiotics change over time. The growing prevalence of antimicrobial resistance has further complicated treatment decisions by reducing the effectiveness of previously reliable therapies against certain pathogens. .

随着既定抗生素的疗效和安全性特征随时间发生变化，治疗格局也在不断演变。抗菌药物耐药性的日益普遍进一步复杂化了治疗决策，因为它降低了以往对某些病原体可靠疗法的有效性。

As a result, clinicians must carefully select antibiotic regimens based on local resistance trends, suspected causative pathogens, disease severity, and individual patient characteristics.

因此，临床医生必须根据当地的耐药趋势、疑似致病菌、疾病严重程度以及患者个体特征，谨慎选择抗生素治疗方案。

The introduction of newer antibiotics has expanded the therapeutic options available for CAP in recent years.

近年来，新型抗生素的问世扩大了社区获得性肺炎（CAP）的治疗选择。

Agents such as

诸如以下代理：

omadacycline (NUZYRA), delafloxacin (BAXDELA), and lefamulin (XENLETA)

奥马环素（NUZYRA）、德拉沙星（BAXDELA）和来法莫林（XENLETA）

have strengthened the CAP treatment armamentarium, particularly for patients who are unsuitable for or do not adequately respond to conventional therapies.

增强了社区获得性肺炎（CAP）的治疗手段，尤其适用于不适合或对传统疗法反应不足的患者。

With broader antimicrobial coverage and, in some cases, novel mechanisms of action, these therapies provide additional options for managing infections caused by a diverse range of CAP pathogens.

凭借更广泛的抗菌谱以及在某些情况下的新颖作用机制，这些疗法为管理由多种社区获得性肺炎（CAP）病原体引起的感染提供了更多选择。

Several antibiotics are also approved for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), including

多种抗生素也已获批用于治疗医院获得性细菌性肺炎（HABP）和呼吸机相关性细菌性肺炎（VABP），包括

cefiderocol (FETROJA), ceftazidime-avibactam (AVYCAZ), telavancin (VIBATIV)

头孢地罗（FETROJA）、头孢他啶-阿维巴坦（AVYCAZ）、特拉万星（VIBATIV）

, and the combination of

，以及……的组合

ceftolozane and tazobactam (ZERBAXA)

头孢洛扎和他唑巴坦（ZERBAXA）

, among others.

，等等。

By comparison, the pipeline for emerging therapies specifically targeting CAP remains relatively limited, although ongoing research and clinical development programs are focused on addressing unmet treatment needs.

相比之下，专门针对社区获得性肺炎（CAP）的新兴疗法研发管线仍然相对有限，尽管当前的研究和临床开发项目正致力于满足尚未被满足的治疗需求。

The emerging community-acquired bacterial pneumonia (CABP) pipeline includes candidates such as

新兴的社区获得性细菌性肺炎（CABP）研发管线包括以下候选药物：

CAL02

CAL02

, developed by Eagle Pharmaceuticals and Combioxin SA, and

由Eagle Pharmaceuticals和Combioxin SA开发，并且

AON-D21

AON-D21

from APTARION Biotech, among others.

来自APTARION Biotech等公司。

These investigational therapies employ innovative approaches aimed at overcoming antimicrobial resistance and improving clinical outcomes, particularly among patients with severe CABP.

这些在研疗法采用创新方法，旨在克服抗菌药物耐药性并改善临床结局，尤其是在患有严重社区获得性细菌性肺炎（CABP）的患者中。

Overall, the availability of both established and recently approved antibiotics has broadened the treatment landscape for CAP, including cases associated with complications or resistance concerns.

总体而言，既有抗生素和近期获批抗生素的可及性拓宽了社区获得性肺炎（CAP）的治疗格局，包括与并发症或耐药性问题相关的病例。

Commonly used antimicrobial regimens include macrolides, either alone or in combination with β-lactams; amoxicillin as monotherapy or combined with a macrolide; fluoroquinolones; and third-generation cephalosporins administered in combination with a macrolide.

常用的抗菌方案包括：大环内酯类（单用或与β-内酰胺类联用）、阿莫西林（单用或与大环内酯类联用）、氟喹诺酮类，以及第三代头孢菌素联合大环内酯类。

Community-Acquired Bacterial Pneumonia Competitive Landscape

社区获得性细菌肺炎竞争格局

Some of the CABP drugs under development include

正在研发中的社区获得性细菌性肺炎（CABP）药物包括

CAL02

CAL02

(Eagle Pharmaceutical/Combioxin),

（Eagle Pharmaceutical/Combioxin）

AON-D21

AON-D21

(APTARION Biotech),

（APTARION Biotech）

Trimodulin

曲莫杜林

(BT588; Biotest AG), and others.

（BT588；Biotest AG）等。

Eagle Pharmaceutical/Combioxin's CAL02

Eagle Pharmaceutical/Combioxin 的 CAL02

is a Phase II-stage therapeutic candidate being developed to address severe infections, particularly community-acquired pneumonia (CAP) among critically ill ICU patients. The treatment consists of liposomes formulated with cholesterol and sphingomyelin, with sphingomyelin incorporated for its distinctive anti-infective properties.

是一种处于II期临床阶段的候选治疗药物，旨在治疗严重感染，特别是重症监护室（ICU）危重患者中的社区获得性肺炎（CAP）。该疗法由含有胆固醇和鞘磷脂的脂质体组成，其中掺入鞘磷脂是利用其独特的抗感染特性。

This formulation highlights the therapeutic potential of antimicrobial lipids in combating bacterial infections..

该制剂突显了抗菌脂质在对抗细菌感染方面的治疗潜力。

CAL02 works by neutralizing bacterial virulence effectors, which play a significant role in the development of organ dysfunction and life-threatening complications associated with severe infections. By targeting these virulence mechanisms rather than solely focusing on bacterial eradication, CAL02 aims to limit disease progression and potentially improve clinical outcomes..

CAL02 通过中和细菌毒力效应因子发挥作用，这些效应因子在严重感染相关的器官功能障碍和危及生命的并发症的发展中起着重要作用。CAL02 旨在通过靶向这些毒力机制，而非仅仅专注于清除细菌，来限制疾病进展并可能改善临床结局。

The candidate has received

候选人已收到

Fast Track and Qualified Infectious Disease Product (QIDP) designations

快速通道认定和合格传染病产品（QIDP）认定

from the U.S. FDA. These regulatory designations can provide an additional five years of market exclusivity, potentially extending the total exclusivity period to eight or ten years.

来自美国食品药品监督管理局（FDA）。这些监管认定可提供额外的五年市场独占期，可能将总独占期延长至八年或十年。

APTARION Biotech's AON-D21

阿普塔里昂生物科技公司的AON-D21

is another therapeutic candidate currently undergoing Phase II clinical development. It is a PEGylated, L-configured aptamer, a synthetic molecule engineered to selectively bind to specific biological targets. AON-D21 is designed to modulate the complement pathway by selectively binding to and neutralizing C5a, a key component of the immune system..

是另一种目前正在接受II期临床开发的治疗候选药物。它是一种聚乙二醇化、L构型的适配体，这是一种经过工程改造以选择性结合特定生物靶点的合成分子。AON-D21旨在通过选择性结合并中和免疫系统的关键组分C5a来调节补体通路。

C5a serves as an important mediator of immune activity and plays a central role in coordinating inflammatory responses. Its broad involvement in immune regulation creates opportunities for C5a-targeted therapies across multiple disease areas, particularly conditions in which excessive or dysregulated immune responses contribute to disease progression..

C5a是免疫活动的重要介质，在协调炎症反应中发挥核心作用。其广泛参与免疫调节，为针对C5a的疗法在多种疾病领域的应用创造了机会，尤其是在那些由过度或失调的免疫反应导致疾病进展的病症中。

The anticipated launch of these emerging therapies are poised to transform the CABP market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the CABP market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth..

这些新兴疗法的预期上市将在未来几年内改变社区获得性细菌性肺炎（CABP）市场的格局。随着这些前沿疗法不断成熟并获得监管批准，预计将重塑 CABP 市场格局，提供新的护理标准，并为医疗创新和经济增长带来机遇。

Discover more about the latest treatments for CABP 2026 @

探索2026年社区获得性细菌性肺炎（CABP）的最新治疗方案 @

Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials

社区获得性细菌肺炎治疗药物临床试验

Community-Acquired Bacterial Pneumonia Epidemiology Segmentation

社区获得性细菌性肺炎的流行病学细分

The CABP epidemiology section provides insights into the historical and current CABP patient pool and forecasted trends for the leading markets. In the US, mild cases of CABP constituted the highest proportion, approximately

CABP流行病学部分提供了对历史和当前CABP患者群体以及主要市场预测趋势的见解。在美国，轻度CABP病例占比最高，约为

50%

百分之五十

of total incident cases, followed by moderate cases at around

占总病例数的，其次是中等病例，约占

35%

百分之三十五

.

。

The CABP treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

《社区获得性细菌性肺炎（CABP）治疗市场报告》提供了2022–2036年研究期间主要市场的流行病学分析，细分如下：

Total Incident Cases of CABP

社区获得性细菌性肺炎（CABP）总病例数

Gender-specific Cases of CABP

社区获得性细菌性肺炎的性别特异性病例

Severity-specific Cases of CABP

按严重程度分类的社区获得性细菌性肺炎病例

Pathogen-specific Cases of CABP

社区获得性细菌性肺炎（CABP）的病原体特异性病例

Age-specific Cases of CABP

按年龄分组的社区获得性细菌性肺炎病例

Total Treated Cases of CABP

社区获得性肺炎（CABP）总治疗病例数

Community-Acquired Bacterial Pneumonia Market Report Metrics

社区获得性细菌性肺炎市场报告指标

Details

详情

Study Period

学习阶段

2022–2036

2022–2036

Coverage

覆盖范围

7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

700万 [美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本]。

Community-Acquired Bacterial Pneumonia Epidemiology Segmentation

社区获得性细菌性肺炎流行病学细分

Total Incident Cases of CABP, Gender-specific Cases of CABP, Severity-specific Cases of CABP, Pathogens-specific Cases of CABP, Age-specific Cases of CABP, and Total Treated Cases of CABP

社区获得性细菌性肺炎（CABP）的总病例数、按性别划分的CABP病例数、按严重程度划分的CABP病例数、按病原体划分的CABP病例数、按年龄划分的CABP病例数，以及CABP的总治疗病例数

Key Community-Acquired Bacterial Pneumonia Companies

社区获得性细菌性肺炎领域的主要企业

Eagle Pharmaceutical, Combioxin, APTARION Biotech, Biotest AG, Nabriva Therapeutics, Paratek Pharmaceutical, and others

鹰制药公司、Combioxin公司、APTARION生物技术公司、Biotest股份公司、Nabriva治疗公司、Paratek制药公司及其他公司

Key Community-Acquired Bacterial Pneumonia Therapies

社区获得性细菌性肺炎的主要疗法

CAL02, AON-D21, Trimodulin (BT588), XENLETA, NUZYRA, and others

CAL02、AON-D21、Trimodulin（BT588）、XENLETA、NUZYRA 等

Scope of the

范围

Community-Acquired Bacterial Pneumonia

社区获得性细菌性肺炎

Market Report

市场报告

Community-Acquired Bacterial Pneumonia Patient Population Forecast

社区获得性细菌性肺炎患者人群预测

Community-Acquired Bacterial Pneumonia Therapeutics Market Size

社区获得性细菌肺炎治疗药物市场规模

Community-Acquired Bacterial Pneumonia Pipeline Analysis

社区获得性细菌性肺炎研发管线分析

Community-Acquired Bacterial Pneumonia Market Size and Trends

社区获得性细菌性肺炎市场规模与趋势

Community-Acquired Bacterial Pneumonia Market Opportunity

社区获得性细菌性肺炎市场机遇

Community-Acquired Bacterial Pneumonia Market Unmet Needs

社区获得性细菌肺炎市场的未满足需求

KOL's Views on Community-Acquired Bacterial Pneumonia

关键意见领袖对社区获得性细菌性肺炎的观点

Community-Acquired Bacterial Pneumonia Market Access and Reimbursement

社区获得性细菌性肺炎的市场准入与报销

Download the report to understand the CABP treatment market @

下载报告以了解社区获得性细菌性肺炎（CABP）治疗市场

Community-Acquired Bacterial Pneumonia Drugs

社区获得性细菌性肺炎药物

Table of Contents

目录

1

1

Community-Acquired Bacterial Pneumonia Market Key Insights

社区获得性细菌性肺炎市场关键洞察

2

2

Community-Acquired Bacterial Pneumonia Market Report Introduction

社区获得性细菌性肺炎市场报告简介

3

3

Executive Summary

执行摘要

4

4

Key Events

关键事件

5

5

Epidemiology and Market Methodology

流行病学与市场方法论

6

6

Community-Acquired Bacterial Pneumonia (CABP) Market Overview at a Glance

社区获得性细菌性肺炎（CABP）市场概览

6.1

6.1

Clinical Landscape Analysis (By Phase, Molecule Type, and RoA)

临床格局分析（按阶段、分子类型和作用机制）

6.2

6.2

Market Share (%) Distribution of CABP by Therapies in the 7MM, in 2025

2025年七个主要市场（7MM）中按疗法划分的社区获得性细菌性肺炎（CABP）市场份额（%）分布

6.3

6.3

Market Share (%) Distribution of CABP by Therapies in the 7MM, in 2036

2036年七个主要国家（7MM）社区获得性细菌性肺炎（CABP）按治疗方案划分的市场份额（%）分布

7

7

Disease Background and Overview

疾病背景与概述

7.1

7.1

Introduction

引言

7.2

7.2

Etiology

病因学

7.3

7.3

Pathophysiology

病理生理学

7.4

7.4

Signs and Symptoms of CABP

社区获得性细菌性肺炎的体征和症状

7.5

7.5

Clinical Characteristics

临床特征

7.6

7.6

Immunology & Risk Factors

免疫学与风险因素

7.7

7.7

Diagnosis

诊断

7.8

7.8

Prognosis

预后

7.9

7.9

Diagnostic Biomarkers for CABP

社区获得性细菌性肺炎（CABP）的诊断生物标志物

8

8

Treatment and Management

治疗与管理

8.1

8.1

Antibiotic therapy

抗生素治疗

8.2

8.2

Diuretics

利尿剂

8.3

8.3

Corticosteroids

皮质类固醇

8.4

8.4

Later management

后期管理

8.5

8.5

Diagnostic and Treatment Guidelines

诊断与治疗指南

9

9

Epidemiology and Patient Population

流行病学与患者人群

9.1

9.1

Key Findings

主要发现

9.2

9.2

Assumptions and Rationale

假设与理由

9.3

9.3

Total Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in the 7MM

七大主要市场（7MM）中社区获得性细菌性肺炎（CABP）的总发病病例数

9.4

9.4

The United States

美国

9.5.1

9.5.1

Incident Cases of Community-Acquired Bacterial Pneumonia (CABP)

社区获得性细菌性肺炎（CABP）的发病病例

9.5.2

9.5.2

Gender-specific Cases of Community-Acquired Bacterial Pneumonia (CABP)

社区获得性细菌性肺炎（CABP）的性别特异性病例

9.5.3

9.5.3

Severity-specific Cases of Community-Acquired Bacterial Pneumonia (CABP)

社区获得性细菌性肺炎（CABP）的严重程度特异性病例

9.5.4

9.5.4

Pathogen-specific Cases of Community-Acquired Bacterial Pneumonia (CABP)

社区获得性细菌性肺炎（CABP）的病原体特异性病例

9.5.5

9.5.5

Age-specific Cases of Community-Acquired Bacterial Pneumonia (CABP)

社区获得性细菌性肺炎（CABP）的年龄别病例数

9.5.6

9.5.6

Total treated Cases of Community-Acquired Bacterial Pneumonia (CABP)

社区获得性细菌性肺炎（CABP）治疗病例总数

9.6

9.6

EU4 and the UK

欧盟四国与英国

9.7

9.7

Japan

日本

10

10

Patient Journey

患者旅程

11

十一

Marketed CABP Therapies

已上市的社区获得性细菌性肺炎（CABP）治疗药物

11.1

11.1

Marketed Competitive Landscape

市场竞争格局

11.2

11.2

Lefamulin (XENLETA): Nabriva Therapeutics

lefamulin（XENLETA）：Nabriva Therapeutics

11.2.1

11.2.1

Drug Description

药物说明

11.2.2

11.2.2

Regulatory Milestones

监管里程碑

11.2.3

11.2.3

Other Developmental Activities

其他发展性活动

11.2.4

11.2.4

Summary of Pivotal Trials

关键试验总结

11.2.5

11.2.5

Clinical Development

临床开发

11.2.5.1

11.2.5.1

Clinical Trial Information

临床试验信息

11.2.6

11.2.6

Safety and Efficacy

安全性与有效性

11.2.7

11.2.7

Analyst's Views

分析师观点

11.3

11.3

Omadacycline (NUZYRA): Paratek Pharmaceuticals

奥马环素（NUZYRA）：Paratek Pharmaceuticals

List will be continued in the report…

列表将在报告中继续……

12

十二

Emerging CABP Drugs

新兴的社区获得性细菌性肺炎（CABP）药物

12.1

12.1

Emerging Competitive Landscape

新兴竞争格局

12.2

12.2

CAL02: Eagle Pharmaceutical/Combioxin SA

CAL02：伊格尔制药/Combioxin SA

12.2.1

12.2.1

Drug Description

药物说明

12.2.2

12.2.2

Other Developmental Activities

其他发展性活动

12.2.3

12.2.3

Clinical Development

临床开发

12.2.3.1

12.2.3.1

Clinical Trials Information

临床试验信息

12.2.4

12.2.4

Safety and Efficacy

安全性与有效性

12.2.5

12.2.5

Analyst's Views

分析师观点

12.3

12.3

AON-D21 (anti-C5a): APTARION Biotech AG

AON-D21（抗C5a）：APTARION Biotech AG

List will be continued in the report…

列表将在报告中继续……

13

13

Other Therapies: Generics

其他疗法：仿制药

13.1

13.1

Amoxicillin

阿莫西林

13.2

13.2

Azithromycin

阿奇霉素

13.3

13.3

Clarithromycin

克拉霉素

13.4

13.4

Doxycycline

多西环素

13.5

13.5

Moxifloxacin

莫西沙星

13.6

13.6

Vaccine

疫苗

14

14

Community-Acquired Bacterial Pneumonia Market: 7MM Analysis

社区获得性细菌性肺炎市场：七国市场分析

14.1

14.1

Key Findings

主要发现

14.2

14.2

Community-Acquired Bacterial Pneumonia Market Outlook

社区获得性细菌性肺炎市场前景

14.3

14.3

Conjoint analysis

联合分析

14.4

14.4

Key Community-Acquired Bacterial Pneumonia Market Forecast Assumptions

社区获得性细菌性肺炎市场预测的关键假设

14.5

14.5

Total Market Size of Community-Acquired Bacterial Pneumonia (CABP) in the 7 MM

七大主要市场社区获得性细菌性肺炎（CABP）的总体市场规模

14.6

14.6

Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies In 7MM

七大主要市场（7MM）中社区获得性细菌性肺炎（CABP）按疗法划分的市场规模

14.7

14.7

The United States CABP Market Size

美国社区获得性细菌性肺炎（CABP）市场规模

14.7.1

14.7.1

Total Market Size of Community-Acquired Bacterial Pneumonia (CABP) in the United States

美国社区获得性细菌性肺炎（CABP）的总体市场规模

14.7.2

14.7.2

Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies in the United States

美国社区获得性细菌性肺炎（CABP）按疗法划分的市场规模

14.8

14.8

EU4 and the UK CABP Market

欧盟4国及英国CABP市场

14.9

14.9

Japan CABP Market Size

日本社区获得性细菌性肺炎（CABP）市场规模

15

十五

KOL Views

KOL观点

16

十六

Unmet Needs

未满足的需求

17

17

SWOT Analysis

SWOT分析

18

十八

CABP Market Access and Reimbursement

社区获得性细菌性肺炎（CABP）的市场准入与报销

19

十九

Bibliography

参考文献

20

二十

Community-Acquired Bacterial Pneumonia Market Report Methodology

社区获得性细菌性肺炎市场报告方法论

Related Reports

相关报告

Community-Acquired Bacterial Pneumonia Clinical Trial Analysis

社区获得性细菌性肺炎临床试验分析

Community-Acquired Bacterial Pneumonia Pipeline – 2026

社区获得性细菌性肺炎研发管线 – 2026

report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CABP companies, including

报告提供了关于管线格局、管线药物概况（包括临床和非临床阶段产品）以及关键社区获得性细菌性肺炎（CABP）企业的全面洞察，包括

Mesoblast, Taiwan Liposome Company, Biosplice, Centrexion Therapeutics, Latigo Biotherapeutics, Pacira BioSciences, Contineum Therapeutics, Tris Pharma, Flexion, Taisho Pharmaceutical, Bioventus,

Mesoblast、台湾脂质体公司、Biosplice、Centrexion Therapeutics、Latigo Biotherapeutics、Pacira BioSciences、Contineum Therapeutics、Tris Pharma、Flexion、大正制药、Bioventus，

and others.

以及其他。

Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Market

医院获得性和呼吸机相关性细菌性肺炎市场

Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia

医院获得性及呼吸机相关性细菌性肺炎

Market Insights, Epidemiology, and Market Forecast

市场洞察、流行病学及市场预测

– 2036

– 2036

report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HABP/VABP companies, including

报告提供对疾病的深入理解、历史及预测流行病学，以及市场趋势、市场驱动因素、市场障碍和关键HABP/VABP公司，包括

Basilea, Merck, Shionogi, Pfizer, Aridis Pharmaceuticals, Polyphor, Aerucin, Motif Bio,

巴塞尔大学、默克、盐野义、辉瑞、Aridis Pharmaceuticals、Polyphor、Aerucin、Motif Bio，

and others.

以及其他。

Pneumonia Market

肺炎市场

Pneumonia Market Insights, Epidemiology, and Market Forecast – 2036

肺炎市场洞察、流行病学及市场预测 – 2036

report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pneumonia companies including

报告深入解析了该疾病、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒和包括在内的关键肺炎企业

Aridis Pharmaceuticals, Aptarion Biotech, Biotest AG, Vaxcyte, Inc., CanSinoBIO, Inventprise, BioVersys,

Aridis Pharmaceuticals，Aptarion Biotech，Biotest AG，Vaxcyte, Inc.，康希诺生物，Inventprise，BioVersys，

and others.

以及其他。

Bacterial Pneumonia

细菌性肺炎

Market

市场

Bacterial Pneumonia

细菌性肺炎

Market Insights, Epidemiology, and Market Forecast

市场洞察、流行病学及市场预测

–

–

2036

2036

report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bacterial pneumonia companies including

本报告深入剖析了疾病概况、历史及预测流行病学数据，以及市场趋势、市场驱动因素、市场壁垒和细菌性肺炎领域的主要企业，包括

Pfizer, Forecast Laboratories, Melinta Therapeutics Inc., Merck Sharp & Dohme LLC, Melinta Therapeutics Inc., Evopoint Biosciences Inc., Paratek Pharmaceuticals Inc., Wockhardt, Clarametyx Biosciences Inc., AstraZeneca, Cumberland Pharmaceuticals, Eagle Pharmaceuticals Inc., Bayer

辉瑞公司、Forecast Laboratories、Melinta Therapeutics Inc.、默沙东有限责任公司、Melinta Therapeutics Inc.、Evopoint Biosciences Inc.、Paratek Pharmaceuticals Inc.、Wockhardt、Clarametyx Biosciences Inc.、阿斯利康、Cumberland Pharmaceuticals、Eagle Pharmaceuticals Inc.、拜耳

,

，

and others.

以及其他。

About

关于

DelveInsight

DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

DelveInsight 是一家领先的商业咨询和市场研究公司，专注于生命科学领域。它通过提供全面的端到端解决方案来帮助制药公司提升绩效。通过我们基于订阅的平台 PharmDelve，您可以轻松获取所有医疗保健和制药市场研究报告。

.

。

Contact Us

联系我们

Shruti Thakur

什鲁蒂·塔库尔

[email protected]

[email protected]

+14699457679

+14699457679

www.delveinsight.com

www.delveinsight.com

SOURCE DelveInsight Business Research, LLP

来源：DelveInsight Business Research, LLP

21

二十一

%

百分之

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示